Business Context and Reporting Period
This Form 8-K, dated January 23, 2023, reports on Oaktree Specialty Lending Corporation (OCSL), a Delaware corporation. The filing primarily documents the consummation of the previously announced mergers with Oaktree Strategic Income II, Inc. (OSI2). As part of the transaction, OCSL issued approximately 15,860,200 shares of its common stock to former OSI2 stockholders at an exchange ratio of 0.9115 shares of OCSL for each share of OSI2. The filing also details the entry into a new investment advisory agreement and the assumption of a significant credit facility.
Key Financial Metrics and Agreements
- Debt and Liquidity: OCSL assumed the OSI2 Citibank Facility, a senior secured revolving credit facility with a maximum commitment of $250 million. As of January 23, 2023, the outstanding balance was $225.0 million. The facility matures on January 26, 2025, with a reinvestment period ending May 26, 2023.
- Net Asset Value (NAV): The adjusted NAV per share of OCSL common stock as of January 20, 2023, was estimated at $19.88 (post 1-for-3 reverse stock split). The adjusted NAV per share of OSI2 was estimated at $18.12.
- Management Fees: Under the new A&R Advisory Agreement, OCSL waived an aggregate of $9.0 million in base management fees payable to Oaktree Fund Advisors, LLC. This includes $6.0 million in the first year post-merger and $3.0 million in the second year.
- Interest Rates: Borrowings under the Citibank Facility bear interest based on LIBOR plus a spread. During the reinvestment period, the spread is the greater of a weighted average (1.65% for syndicated loans, 2.25% for others) or 1.85%. Post-reinvestment, the spread increases to 3.00%.
Material Changes Versus Prior Period
The most significant change is the structural consolidation of OSI2 into OCSL, resulting in the issuance of new equity and the assumption of OSI2's debt obligations. The filing notes the termination of the previous investment advisory agreement (dated March 19, 2021) and a related letter agreement (dated September 14, 2022), replaced by the Second Amended and Restated Investment Advisory Agreement. Additionally, the filing references a 1-for-3 reverse stock split effective for trading on January 23, 2023, which adjusts the share count and price metrics compared to prior reporting periods.
Guidance, Outlook, and Risks
- Accounting Adjustments: The new advisory agreement revises the calculation of incentive fees to exclude merger-related accounting adjustments (such as amortization of purchase premiums) that would otherwise artificially increase Pre-Incentive Fee Net Investment Income or capital gains.
- Covenants and Restrictions: The OSI2 Citibank Facility imposes limitations on fund usage, sector concentrations, loan size, tenor, and minimum investment ratings. It also includes requirements for interest coverage and collateral quality; violations could trigger acceleration of debt.
- NAV Disclaimer: Management explicitly states that the NAV figures provided ($19.88 for OCSL and $18.12 for OSI2) were determined solely for the purposes of the Merger Agreement and were not reviewed for financial statement preparation. They may not be indicative of actual NAV as of December 31, 2022, or March 31, 2023.
Investor Verification Checklist
- Verify the exact terms of the 1-for-3 reverse stock split and its impact on historical share counts and per-share metrics.
- Review the full text of the OSI2 Citibank Facility (Exhibits 10.2-10.7) to understand specific covenants, collateral requirements, and the calculation of the borrowing base.
- Confirm the impact of the $9.0 million fee waiver on future earnings per share and net investment income calculations.
- Monitor the reinvestment period end date (May 26, 2023) for the Citibank Facility, as mandatory amortization payments will commence thereafter.
- Check subsequent filings for the official audited Net Asset Value as of December 31, 2022, to compare against the merger-estimated figures.